Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)
- PMID: 11182372
- DOI: 10.1016/s8756-3282(00)00430-0
Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)
Abstract
A key feature of postmenopausal osteoporosis is the loss of trabecular bone mass and connectivity. The current study focuses on these parameters in the assessment of long-term (12 and 18 months) parathyroid hormone (PTH) therapy and its withdrawal (6 months) in the ovariectomized cynomolgus monkey (Macaca fascicularis), a well-characterized model for bone changes associated with postmenopausal osteoporosis. We used static and dynamic histomorphometric parameters to assess the amount and architecture of cancellous bone in four clinically important sites for osteoporotic fractures, including the lumbar vertebra, femoral neck, distal radius, and iliac crest. Recombinant human PTH(1-34) was administered daily to two groups for 18 months at 1.0 microg/kg per day (n = 19) and 5.0 microg/kg per day (n = 21). To study the effects of PTH withdrawal, two groups were administered PTH(1-34) daily for 12 months at 1.0 microg/kg per day (n = 20) and 5.0 microg/kg per day (n = 20), followed by daily administration of vehicle for 6 months. Sham-ovariectomized and ovariectomized (ovx) groups each received daily injections of vehicle for 18 months. Treatment with PTH had minimal effects on bone formation rates at the timepoints studied, but markedly increased cancellous bone volume relative to ovx monkeys in iliac crest biopsies at 6 and 15 months, as well as in terminal specimens of lumbar vertebrae, femoral neck, and distal radius after 18 months. At all sites, PTH significantly improved trabecular architecture, as evidenced by increased trabecular number (Tb.N) and decreased trabecular separation (Tb.Sp), with no significant change in trabecular thickness (Tb.Th). The mechanism of these structural changes is suggested by qualitative observations of trabecular tunneling observed in the iliac crest and vertebra. Longitudinal tunneling of thickened individual trabeculae is hypothesized to convert them into multiple trabeculae, resulting in a normalization of Tb.Th, but an increase in Tb.N. A significant positive effect on cancellous bone volume was still apparent after a 3-6 month withdrawal period following 12 months of PTH treatment in the iliac crest, vertebra, and femoral neck. Corresponding increases in Tb.N and decreases in Tb.Sp also remained significant after PTH withdrawal at these three sites. The distal radius was relatively insensitive to PTH treatment or its withdrawal, compared with the other bones. In summary, PTH therapy dramatically improved cancellous bone mass and architecture in both axial and appendicular sites.
Similar articles
-
Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.J Bone Miner Res. 2007 Feb;22(2):260-73. doi: 10.1359/jbmr.061101. J Bone Miner Res. 2007. PMID: 17087625
-
Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis).Bone. 1999 Sep;25(3):301-9. doi: 10.1016/s8756-3282(99)00166-0. Bone. 1999. PMID: 10495134
-
Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84.Bone. 2008 Jun;42(6):1175-83. doi: 10.1016/j.bone.2008.01.029. Epub 2008 Feb 29. Bone. 2008. PMID: 18387869
-
Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis.Treat Endocrinol. 2002;1(3):175-90. doi: 10.2165/00024677-200201030-00005. Treat Endocrinol. 2002. PMID: 15799210 Review.
-
Bone microstructure in osteoporosis: transilial biopsy and histomorphometry.Top Magn Reson Imaging. 2002 Oct;13(5):297-305. doi: 10.1097/00002142-200210000-00002. Top Magn Reson Imaging. 2002. PMID: 12464743 Review.
Cited by
-
The combined effect of parathyroid hormone and bone graft on implant fixation.J Bone Joint Surg Br. 2011 Jan;93(1):131-9. doi: 10.1302/0301-620X.93B1.24261. J Bone Joint Surg Br. 2011. PMID: 21196558 Free PMC article.
-
Effects of anti-osteoporosis medications on fracture healing.Curr Osteoporos Rep. 2011 Sep;9(3):149-55. doi: 10.1007/s11914-011-0065-0. Curr Osteoporos Rep. 2011. PMID: 21698357 Review.
-
Systemic intermittent parathyroid hormone treatment improves osseointegration of press-fit inserted implants in cancellous bone.Acta Orthop. 2012 Aug;83(4):411-9. doi: 10.3109/17453674.2012.702388. Epub 2012 Aug 10. Acta Orthop. 2012. PMID: 22880714 Free PMC article.
-
Signs of irreversible architectural changes occur early in the development of experimental osteoporosis as assessed by in vivo micro-CT.Osteoporos Int. 2008 Oct;19(10):1409-19. doi: 10.1007/s00198-008-0581-7. Epub 2008 Mar 29. Osteoporos Int. 2008. PMID: 18373058
-
Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.J Bone Miner Metab. 2005;23 Suppl:62-8. doi: 10.1007/BF03026325. J Bone Miner Metab. 2005. PMID: 15984416
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical